Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 5/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5723095 | 0.88 | FFAR4 (0.35) | PDE4BPDE4DFFAR4CTSAPDE4A | |
| SCHEMBL5722918 | 0.88 | PDE4B (0.40) | PDE4BPDE4DHIF1APDE4APDE4C | |
| SCHEMBL5722908 | 0.87 | PDE4D (0.40) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6833270 | 0.86 | PDE4D (0.39) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL5723085 | 0.85 | FFAR4 (0.33) | PDE4BPDE4DFFAR4CTSAPDE4A | |
| SCHEMBL5722871 | 0.82 | PDE4B (0.40) | PDE4BPDE4DFFAR4HIF1APDE4A | |
| SCHEMBL6942675 | 0.79 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6833336 | 0.79 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL5722809 | 0.79 | PDE4A (0.44) | PDE4BPDE4DHIF1APDE4APDE4C | |
| SCHEMBL6837937 | 0.78 | PDE4B (0.39) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0771794-B1 | OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KK (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6716987-B1 | PHOSPHODIESTERASE IV INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-6514996-B2 | Derivatives of benzofuran or benzodioxole | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-0771794-A1 | OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | CBR1, CBR3, CYC1 | PDE4B 4877/4885PDE4D 4870/4885FFAR4 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.